192 related articles for article (PubMed ID: 19657307)
41. Assessing tumor response to therapy.
Weber WA
J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
[TBL] [Abstract][Full Text] [Related]
42. [Lung cancer detected by fluorodeoxyglucose-positron emission tomography/computed tomography in the course of Mycobacterium avium infection; report of a case].
Adachi K; Kaneda M; Sakai T; Fujimoto H; Ibata H; Omoto Y; Watanabe F
Kyobu Geka; 2009 Oct; 62(11):1019-21. PubMed ID: 19827559
[TBL] [Abstract][Full Text] [Related]
43. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
[TBL] [Abstract][Full Text] [Related]
44. Application of 18F-fluorodeoxyglucose positron emission tomography/computerized tomography in mantle cell lymphoma.
Yang S; Fu L; AbuduRxiti M; Wu J; Wang Q; Qin Y; Zou X; Li H
Nucl Med Commun; 2020 May; 41(5):477-484. PubMed ID: 32168265
[TBL] [Abstract][Full Text] [Related]
45. [FDG PET/CT and childhood Hodgkin lymphoma].
Montravers F; Kerrou K; Huchet V; Pascal O; Talbot JN
Arch Pediatr; 2009 Jun; 16(6):669-71. PubMed ID: 19541124
[No Abstract] [Full Text] [Related]
46. Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck.
Rodrigues RS; Bozza FA; Christian PE; Hoffman JM; Butterfield RI; Christensen CR; Heilbrun M; Wiggins RH; Hunt JP; Bentz BG; Hitchcock YJ; Morton KA
J Nucl Med; 2009 Aug; 50(8):1205-13. PubMed ID: 19617339
[TBL] [Abstract][Full Text] [Related]
47. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
48. The evolving role of PET-CT in the management of esophageal cancer.
Chuang HH; Macapinlac HA
Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):201-9. PubMed ID: 19293768
[TBL] [Abstract][Full Text] [Related]
49. Outcome of deferred initial therapy in mantle-cell lymphoma.
Martin P; Chadburn A; Christos P; Weil K; Furman RR; Ruan J; Elstrom R; Niesvizky R; Ely S; Diliberto M; Melnick A; Knowles DM; Chen-Kiang S; Coleman M; Leonard JP
J Clin Oncol; 2009 Mar; 27(8):1209-13. PubMed ID: 19188674
[TBL] [Abstract][Full Text] [Related]
50. Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index.
Møller MB; Pedersen NT; Christensen BE
Br J Haematol; 2006 Apr; 133(1):43-9. PubMed ID: 16512827
[TBL] [Abstract][Full Text] [Related]
51. [Usefulness of FDG-PET/CT for the diagnosis of intravascular large B-cell lymphoma presenting with fever of unknown origin and renal dysfunction].
Yago K; Yanagita S; Aono M; Matsuo K; Shimada H
Rinsho Ketsueki; 2009 Jun; 50(6):499-502. PubMed ID: 19571511
[TBL] [Abstract][Full Text] [Related]
52. Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma.
Alavi A; Shrikanthan S; Aydin A; Talanow R; Schuster S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):261-6. PubMed ID: 21658653
[TBL] [Abstract][Full Text] [Related]
53. Positron emission tomography in mantle cell lymphoma.
Brepoels L; Stroobants S; De Wever W; Dierickx D; Vandenberghe P; Thomas J; Mortelmans L; Verhoef G; De Wolf-Peeters C
Leuk Lymphoma; 2008 Sep; 49(9):1693-701. PubMed ID: 18798104
[TBL] [Abstract][Full Text] [Related]
54. Lungs of patients with acute respiratory distress syndrome show diffuse inflammation in normally aerated regions: a [18F]-fluoro-2-deoxy-D-glucose PET/CT study.
Bellani G; Messa C; Guerra L; Spagnolli E; Foti G; Patroniti N; Fumagalli R; Musch G; Fazio F; Pesenti A
Crit Care Med; 2009 Jul; 37(7):2216-22. PubMed ID: 19487931
[TBL] [Abstract][Full Text] [Related]
55. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network.
Tiemann M; Schrader C; Klapper W; Dreyling MH; Campo E; Norton A; Berger F; Kluin P; Ott G; Pileri S; Pedrinis E; Feller AC; Merz H; Janssen D; Hansmann ML; Krieken H; Möller P; Stein H; Unterhalt M; Hiddemann W; Parwaresch R;
Br J Haematol; 2005 Oct; 131(1):29-38. PubMed ID: 16173960
[TBL] [Abstract][Full Text] [Related]
56. Mantle cell lymphoma in the orbital and adnexal region.
Rasmussen P; Sjö LD; Prause JU; Ralfkiaer E; Heegaard S
Br J Ophthalmol; 2009 Aug; 93(8):1047-51. PubMed ID: 19429588
[TBL] [Abstract][Full Text] [Related]
57. [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma.
Gill S; Wolf M; Prince HM; Januszewicz H; Ritchie D; Hicks RJ; Seymour JF
Clin Lymphoma Myeloma; 2008 Jun; 8(3):159-65. PubMed ID: 18650179
[TBL] [Abstract][Full Text] [Related]
58. Positron emission tomography/computed tomography potential pitfalls and artifacts.
Wang X; Koch S
Curr Probl Diagn Radiol; 2009; 38(4):156-69. PubMed ID: 19464586
[TBL] [Abstract][Full Text] [Related]
59. Utility of positron emission tomography scans in mantle cell lymphoma.
Hosein PJ; Pastorini VH; Paes FM; Eber D; Chapman JR; Serafini AN; Alizadeh AA; Lossos IS
Am J Hematol; 2011 Oct; 86(10):841-5. PubMed ID: 21922524
[TBL] [Abstract][Full Text] [Related]
60. Improvement of overall survival in advanced stage mantle cell lymphoma.
Herrmann A; Hoster E; Zwingers T; Brittinger G; Engelhard M; Meusers P; Reiser M; Forstpointner R; Metzner B; Peter N; Wörmann B; Trümper L; Pfreundschuh M; Einsele H; Hiddemann W; Unterhalt M; Dreyling M
J Clin Oncol; 2009 Feb; 27(4):511-8. PubMed ID: 19075279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
